Jeffrey V. Matous, MD

Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Jeffrey V. Matous, MD, discusses factors to be considered when determining the optimal sequencing of bispecific antibodies in multiple myeloma.

Jeffrey V. Matous, MD, discusses future directions of CAR T-cell therapy in multiple myeloma, highlighting the potential promise of novel targets beyond BCMA.

Jeffrey V. Matous, MD, discusses upcoming and ongoing clinical trials in multiple myeloma being conducted at the Colorado Blood Cancer Institute.

Jeffrey V. Matous, MD, discusses the benefit derived from the phase 3 IKEMA trial in patients with relapsed/refractory multiple myeloma, highlighting the key factors to take into account when evaluating patients for relapsed/refractory disease within this treatment space.

Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.